Plimoth Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Plimoth Trust’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Sell	491 -22	-4%	-$15K	0.06%	150
2026 Q1	$396K	Hold	513	–	–	0.09%	131
2025 Q4	$396K	Sell	513 -48	-9%	-$32.6K	0.09%	130
2025 Q3	$315K	Sell	561 -227	-29%	-$128K	0.07%	146
2025 Q2	$414K	Sell	788 -19	-2%	-$10.6K	0.1%	125
2025 Q1	$512K	Sell	807 -30	-4%	-$20.6K	0.13%	117
2024 Q4	$596K	Hold	837	–	–	0.15%	108
2024 Q3	$880K	Sell	837 -71	-8%	-$79K	0.22%	95
2024 Q2	$954K	Sell	908 -60	-6%	-$58.2K	0.25%	85
2024 Q1	$932K	Sell	968 -164	-14%	-$156K	0.25%	86
2023 Q4	$994K	Sell	1,132 -1,324	-54%	-$1.09M	0.29%	81
2023 Q3	$2.02M	Sell	2,456 -188	-7%	-$148K	0.63%	56
2023 Q2	$1.9M	Sell	2,644 -19	-0.7%	-$14.6K	0.57%	60
2023 Q1	$2.19M	Buy	2,663 +40	+2%	+$30.2K	0.68%	56
2022 Q4	$1.89M	Sell	2,623 -75	-3%	-$55.3K	0.61%	59
2022 Q3	$1.86M	Buy	2,698 +206	+8%	+$130K	0.64%	55
2022 Q2	$1.47M	Buy	2,492 +442	+22%	+$287K	0.46%	70
2022 Q1	$1.43M	Buy	2,050 +13	+0.6%	+$8.22K	0.38%	76
2021 Q4	$1.29M	Buy	2,037 +326	+19%	+$200K	0.33%	85
2021 Q3	$1.04M	Buy	1,711 +199	+13%	+$124K	0.29%	91
2021 Q2	$844K	Buy	+1,512	New	+$766K	0.24%	100

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Plimoth Trust's REGN Position: Q2 2026 in Review

Plimoth Trust reduced its Regeneron Pharmaceuticals (REGN) stake by 4.3% in Q2 2026, selling an estimated $15K and leaving 491 shares worth $306K. The position accounts for 0.06% of the portfolio, ranked #150.

Plimoth Trust first reported a position in REGN in Q2 2021 and has held it in 21 quarters since. The position peaked at $2.19M in Q1 2023. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Plimoth Trust held 491 shares of Regeneron Pharmaceuticals worth $306K as of Q2 2026.
Plimoth Trust sold 22 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $15K.
Regeneron Pharmaceuticals made up 0.06% of Plimoth Trust's portfolio in Q2 2026, its #150 holding.
Plimoth Trust first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
Plimoth Trust's Regeneron Pharmaceuticals position peaked at $2.19M in Q1 2023.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Plimoth Trust's 13F filing for Q2 2026, filed 28 Jul 2026.